ClinicalTrials.Veeva

Menu

NIRS Directed Optimal Cerebral Perfusion Pressure on the Outcome of Aneurysmal Subarachnoid Hemorrhage Patients

C

Central South University

Status

Unknown

Conditions

Optimal Cerebral Perfusion Pressure on the Outcome of aSAH Patients

Treatments

Device: Near-infrared spectroscopy (NIRS) and ICM+

Study type

Interventional

Funder types

Other

Identifiers

NCT05003232
20210618

Details and patient eligibility

About

Objectives: To investigate the impact of NIRS directed optimal cerebral perfusion pressure on the outcome of aSAH patients.

Study design: A multicenter, single-blinded, randomized controlled trial. Setting: Departments of critical care medicine of tertiary hospitals in China. Patients: 150 aSAH patients (≥ 18 years old) who admitted to ICU (predicted ICU duration time ≥ 24 hours)

Intervention:

Patients with aSAH will be randomly divided into the control group and the intervention group. The control group will follow the SAH guidelines. The intervention group will be given continuous NIRS and invasive blood pressure monitoring at same time. The correlation curve between the brain oxygenation index or the brain hemoglobin index (ORI/THx) and the blood pressure will be obtained through continuous monitoring. According to the correlation curve, the optimal blood pressure will be determined which provides the optimal CPP. Then the goal of blood pressure (within 5 mmHg of CPPopt) will be maintained as the target of blood pressure management for the intervention group during ICU stay.

Primary outcome: Neurological prognosis (GCS score,GOS score, and NIHSS score when discharge from ICU; GOS score at 6 months), etc.

Predicted duration of the study: 2 years.

Enrollment

150 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age ≥ 18 years;
  • Admitted to ICU because of aSAH.
  • Predicted to stay in ICU ≥ 24 hours
  • Provide written informed consent.

Exclusion criteria

  • Unable to perform NIRS monitoring because of anatomic factors;
  • Patients with severe organ failure;
  • In addition to aneurysmal subarachnoid hemorrhage, there are other serious intracranial diseases (intracranial infection, cerebral hemorrhage, cerebral infarction, brain trauma, other patients after intracranial surgery);
  • Patients with carotid plaque or thrombus;
  • Patients with severe intracranial pneumatosis after craniotomy.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

150 participants in 2 patient groups

Control group
No Intervention group
Optimal MAP group
Experimental group
Treatment:
Device: Near-infrared spectroscopy (NIRS) and ICM+

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems